Targeted Strategies for Today's Evolving Markets

MissionIR Blog

ADMA Biologics (ADMA) Presents at Rodman & Renshaw Conference

ADMA Biologics, Inc. (NASDAQ: ADMA) is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disorder (PIDD) and certain infectious diseases. The company’s product candidates target niche patient populations – including patients suffering from underlying immune deficiency diseases and patients who are immune-compromised for medical reasons. ADMA’s lead product candidate, RI-002, has completed a phase III clinical trial in patients with PIDD, and the company submitted a biologics license application to the FDA on July 31, 2015. For more information, visit the company’s website at

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. For more information on Rodman & Renshaw, visit
This entry was posted in Rodman and Renshaw Conference, Small Cap News. Bookmark the permalink.

Comments are closed.